CytoMed Therapeutics Ltd (GDTC) saw an uptrend of 16.58% in the recent trading with $2.25 being its most recent. The current price level -44.44% lower than the highest price of $4.05 marked by the stock while trading over the past 52-weeks, whereas it is 36.36% higher than the lowest price of $1.65 the company dropped to over past 52-weeks. The latest news story on GDTC appeared in (GlobeNewswire) under the title “CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
CytoMed Therapeutics Ltd Earnings – What Happened With GDTC
Coming around sales and income figures on GDTC Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
GDTC – CytoMed Therapeutics Ltd Stock Earnings Estimates
The perspective of CytoMed Therapeutics Ltd (NASDAQ:GDTC)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.03 for stock’s EPS in the current quarter.
CytoMed Therapeutics Ltd – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 11.54 million. GDTC does have institutional investors; and they hold 0.39% of the stock.
Key Metrics for GDTC
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, CytoMed Therapeutics Ltd has a debt to equity ratio of 0.07.
